| Name | Title | Contact Details |
|---|
Uroplasty is a global medical company committed to offering transformative treatment options through specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Uroplasty’s products include the Urgent® PC Neuromodulation System, a non-drug, non-surgical office-based treatment for Overactive Bladder and associated symptoms of urinary urgency, urinary frequency and urge incontinence. Urgent PC is an FDA-cleared system that delivers PTNS (Percutaneous Tibial Nerve Stimulation) and is also indicated for the treatment of fecal incontinence outside the US market. Uroplasty also offers Macroplastique®, an injectable urethral bulking agent for female stress urinary incontinence primarily due to intrinsic sphincter deficiency. Female SUI only in U.S.; male and female SUI outside the U.S. Uroplasty products are typically used when a patient’s treatment goals are not met after conservative and/or drug therapies. Providers and patients alike appreciate that Uroplasty products provide low-risk, effective alternatives to invasive surgery. And because these treatments can be delivered in an office or outpatient setting, the end result is that more patients are given the opportunity to transform their lives with successful treatment.
ENCOMPASS was established in 1985 as a wholly owned for profit subsidiary of the Iowa Foundation for Medical Care (IFMC). IFMC was established in 1972 through the cooperative efforts of business and physicians in response to increasing demands for
Recent changes in Medicare coding requirements have caused hospitals to suffer from lost revenues, penalties and forfeiture of reimbursements due to inadequate documentation. Founder Dr. Jon Elion, who earlier created the highly successful Heartlab imaging software, tackled this problem with an expert team. The result was the company`s premiere product, ChartWise:CDI, which is the first-to-market Computer-Assisted Clinical Documentation Improvement (CACDI) software system designed to improve precision in quality clinical documentation to support revenue assurance. In February 2014 ChartWise launched an upgraded system, ChartWise 2.0—redefining CDI with powerful new features and an advance new user interface. The program is easy for medical professionals to understand and use, has a light IT footprint, and offers hospitals a way to mitigate risk, maximize reimbursement, and gain insight into their medical documentation improvement efforts. No other program is as robust, or addresses the clinical documentation challenges, the way ChartWise 2.0 does.
NexMed, Inc. (NASDAQ: NEXM), due to its recent acquisition of Bio-Quant, Inc., a revenue-generating specialty contract research organization performing in vitro and in vivo pharmacology services, is now the largest specialty CRO based in San Diego, CA.
Ramona Vna and Hospice is a Hemet, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.